Key result
ICDs deliver appropriate therapy to ~16% of HCM patients alongside low disease-related mortality.
Why the study?
Experience with ICD therapy to prevent sudden death in HCM had largely been derived from relatively small cohorts confined to specific countries or regions.
Does implantable cardioverter-defibrillator (ICD) therapy prevent sudden death and improve survival in high-risk patients with hypertrophic cardiomyopathy?
Cohort (n=3,387)
Yes
Does implantable cardioverter-defibrillator (ICD) therapy prevent sudden death and improve survival in high-risk patients with hypertrophic cardiomyopathy?
In a large international cohort of HCM patients, ICDs effectively terminated life-threatening arrhythmias in 16% of patients, resulting in very low rates of sudden death and high long-term survival.
No takes yet. Share an insight, caveat, or question.
Supports ICD consideration in selected HCM patients; leaves optimal risk stratification open for prospective trials.
Rowin et al. (2026) conducted a cohort in Hypertrophic cardiomyopathy (n=3,387). Implantable cardioverter-defibrillators (ICDs) was evaluated on ≥1 appropriate ICD therapy. Implantable cardioverter-defibrillators delivered appropriate therapy to 16% of patients with hypertrophic cardiomyopathy over a mean follow-up of 7 years, with low HCM-related mortality.